Suche ›

Protein Tyrosine Kinases

From Inhibitors to Useful Drugs

Humana Press,
255,73 € Lieferbar in 5-7 Tagen
Dieses Produkt ist auch verfügbar als:


Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.


Titel: Protein Tyrosine Kinases
Autoren/Herausgeber: Doriano Fabbro, Frank McCormick (Hrsg.)
Aus der Reihe: Cancer Drug Discovery and Development
Ausgabe: Softcover reprint of hardcover 1st ed. 2006

ISBN/EAN: 9781617375347

Seitenzahl: 290
Format: 22,9 x 15,2 cm
Produktform: Taschenbuch/Softcover
Gewicht: 468 g
Sprache: Englisch - Newsletter
Möchten Sie sich für den Newsletter anmelden?

Bitte geben Sie eine gültige E-Mail-Adresse ein.
Lieber nicht